Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
302 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014', provides an overview of the Refractory Acute Myeloid Leukemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Acute Myeloid Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Refractory Acute Myeloid Leukemia Overview 9 Therapeutics Development 10 Pipeline Products for Refractory Acute Myeloid Leukemia - Overview 10 Pipeline Products for Refractory Acute Myeloid Leukemia - Comparative Analysis 11 Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies 12 Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 17 Refractory Acute Myeloid Leukemia - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Refractory Acute Myeloid Leukemia - Products under Development by Companies 21 Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 25 Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 26 AbbVie Inc. 26 Actinium Pharmaceuticals, Inc. 27 Agios Pharmaceuticals, Inc. 28 Altor BioScience Corporation 29 Ambit Biosciences Corporation 30 Amgen Inc. 31 Astellas Pharma Inc. 32 Astex Pharmaceuticals, Inc. 33 AstraZeneca PLC 34 AVEO Pharmaceuticals, Inc. 35 Boehringer Ingelheim GmbH 36 Bristol-Myers Squibb Company 37 Celgene Corporation 38 Conkwest, Inc. 39 Cornerstone Pharmaceuticals, Inc. 40 CTI BioPharma Corp. 41 Eisai Co., Ltd. 42 EpiZyme, Inc. 43 Exelixis, Inc. 44 F. Hoffmann-La Roche Ltd. 45 Fujifilm Corporation 46 GlaxoSmithKline plc 47 Igenica Biotherapeutics, Inc. 48 Incyte Corporation 49 Jiangsu Hansoh Pharmaceutical Co., Ltd. 50 JW Pharmaceutical Corporation 51 Karyopharm Therapeutics, Inc. 52 Kyowa Hakko Kirin Co., Ltd. 53 Les Laboratoires Servier SAS 54 MacroGenics, Inc. 55 Merck & Co., Inc. 56 Millennium Pharmaceuticals, Inc. 57 Novartis AG 58 Piramal Enterprises Limited 59 Plexxikon Inc. 60 Polaris Group 61 Seattle Genetics, Inc. 62 SpectraMab GmbH 63 Sunesis Pharmaceuticals, Inc. 64 Synta Pharmaceuticals Corp. 65 Targa Therapeutics Corp. 66 Tolero Pharmaceuticals, Inc. 67 Verastem, Inc. 68 Refractory Acute Myeloid Leukemia - Therapeutics Assessment 69 Assessment by Monotherapy Products 69 Assessment by Target 70 Assessment by Mechanism of Action 75 Assessment by Route of Administration 78 Assessment by Molecule Type 80 Drug Profiles 82 AG-120 - Drug Profile 82 AG-221 - Drug Profile 84 ALT-801 - Drug Profile 87 alvocidib hydrochloride - Drug Profile 89 AMG-232 - Drug Profile 90 AT-9283 - Drug Profile 91 BI-836858 - Drug Profile 93 binimetinib - Drug Profile 94 bortezomib - Drug Profile 98 brentuximab vedotin - Drug Profile 103 cabozantinib s-malate - Drug Profile 108 cafusertib hydrochloride - Drug Profile 111 Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile 112 Cell Therapy to Target CD33 for Acute Myeloid Leukemia - Drug Profile 113 Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 114 CPI-613 - Drug Profile 115 crenolanib besylate - Drug Profile 117 CST-101 - Drug Profile 119 CWP-291 - Drug Profile 121 DFP-10917 - Drug Profile 123 elesclomol - Drug Profile 124 EPZ-5676 - Drug Profile 126 erlotinib hydrochloride - Drug Profile 127 FF-10501 - Drug Profile 130 ficlatuzumab - Drug Profile 131 gilteritinib - Drug Profile 133 GSK-2879552 - Drug Profile 134 GSK-525762 - Drug Profile 135 HuM-195/rGel - Drug Profile 136 IGN-523 - Drug Profile 137 ilorasertib - Drug Profile 138 imatinib mesylate - Drug Profile 140 indisulam - Drug Profile 142 Iomab-B - Drug Profile 143 KHK-2823 - Drug Profile 145 LGH-447 - Drug Profile 146 MGD-006 - Drug Profile 147 midostaurin - Drug Profile 148 MK-2206 - Drug Profile 150 P-2745 - Drug Profile 153 PD-616 - Drug Profile 154 pegargiminase - Drug Profile 156 PLX-3397 - Drug Profile 159 quizartinib - Drug Profile 161 RG-7775 - Drug Profile 163 ruxolitinib phosphate - Drug Profile 164 S-055746 - Drug Profile 168 selinexor - Drug Profile 169 selumetinib sulfate - Drug Profile 172 Small Molecules to Inhibit MDM2 for Oncology - Drug Profile 175 temozolomide - Drug Profile 176 tigecycline - Drug Profile 178 tosedostat - Drug Profile 179 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 181 Triplebody 19x16x19 - Drug Profile 183 ulocuplumab - Drug Profile 184 venetoclax - Drug Profile 185 vorinostat - Drug Profile 188 vosaroxin - Drug Profile 192 VS-4718 - Drug Profile 194 ZEN-3365 - Drug Profile 195 Refractory Acute Myeloid Leukemia - Recent Pipeline Updates 196 Refractory Acute Myeloid Leukemia - Dormant Projects 284 Refractory Acute Myeloid Leukemia - Discontinued Products 285 Refractory Acute Myeloid Leukemia - Product Development Milestones 286 Featured News & Press Releases 286 Appendix 297 Methodology 297 Coverage 297 Secondary Research 297 Primary Research 297 Expert Panel Validation 297 Contact Us 298 Disclaimer 298
List of Tables Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2014 14 Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Development by Companies, H2 2014 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H2 2014 21 Comparative Analysis by Late Stage Development, H2 2014 22 Comparative Analysis by Clinical Stage Development, H2 2014 23 Comparative Analysis by Early Stage Development, H2 2014 24 Products under Development by Companies, H2 2014 25 Products under Development by Companies, H2 2014 (Contd..1) 26 Products under Development by Companies, H2 2014 (Contd..2) 27 Products under Development by Companies, H2 2014 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2014 29 Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H2 2014 30 Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 31 Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2014 32 Refractory Acute Myeloid Leukemia - Pipeline by Altor BioScience Corporation, H2 2014 33 Refractory Acute Myeloid Leukemia - Pipeline by Ambit Biosciences Corporation, H2 2014 34 Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc., H2 2014 35 Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H2 2014 36 Refractory Acute Myeloid Leukemia - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 37 Refractory Acute Myeloid Leukemia - Pipeline by AstraZeneca PLC, H2 2014 38 Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 39 Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2014 40 Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2014 41 Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H2 2014 42 Refractory Acute Myeloid Leukemia - Pipeline by Conkwest, Inc., H2 2014 43 Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 44 Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H2 2014 45 Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H2 2014 46 Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H2 2014 47 Refractory Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H2 2014 48 Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 49 Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H2 2014 50 Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline plc, H2 2014 51 Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 52 Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H2 2014 53 Refractory Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2014 54 Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H2 2014 55 Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 56 Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 57 Refractory Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H2 2014 58 Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H2 2014 59 Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H2 2014 60 Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 61 Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2014 62 Refractory Acute Myeloid Leukemia - Pipeline by Piramal Enterprises Limited, H2 2014 63 Refractory Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H2 2014 64 Refractory Acute Myeloid Leukemia - Pipeline by Polaris Group, H2 2014 65 Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H2 2014 66 Refractory Acute Myeloid Leukemia - Pipeline by SpectraMab GmbH, H2 2014 67 Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2014 68 Refractory Acute Myeloid Leukemia - Pipeline by Synta Pharmaceuticals Corp., H2 2014 69 Refractory Acute Myeloid Leukemia - Pipeline by Targa Therapeutics Corp., H2 2014 70 Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 71 Refractory Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H2 2014 72 Assessment by Monotherapy Products, H2 2014 73 Number of Products by Stage and Target, H2 2014 76 Number of Products by Stage and Mechanism of Action, H2 2014 80 Number of Products by Stage and Route of Administration, H2 2014 83 Number of Products by Stage and Molecule Type, H2 2014 85 Refractory Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H2 2014 200 Refractory Acute Myeloid Leukemia - Dormant Projects, H2 2014 288 Refractory Acute Myeloid Leukemia - Discontinued Products, H2 2014 289
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
